mAIbe

mAIbe S.r.l. is a private, pre-revenue biotechnology company headquartered in Milan, Italy, with a registered office in Rome. The company is building a proprietary AI/ML platform that integrates physics-based models with generative AI to accelerate and optimize the discovery and development of monoclonal antibody therapies for infectious diseases. Focused on a significant unmet medical need, mAIbe aims to transform mAb R&D by drastically reducing development time and cost, thereby making advanced biologic treatments more accessible. The company is in the pre-clinical/platform development stage and is actively building scientific partnerships to advance its technology.

A proprietary, physics-informed generative artificial intelligence (AI) platform designed for the end-to-end discovery and optimization of monoclonal antibodies (mAbs). It integrates biophysical principles with machine learning to predict and design antibody structures with desired efficacy, stability, and safety profiles, aiming to drastically reduce development time and cost.

mAIbe competes in the crowded AI-driven drug discovery sector against well-funded players like Recursion, Exscientia, and Absci, as well as internal efforts at large pharma. Its differentiation lies in the specific focus on physics-informed AI for infectious disease monoclonal antibodies, a niche with fewer dedicated competitors but significant scientific hurdles.